Life sciences firm Optibiotix Health secures major international deal

A life sciences business which is working to tackle health problems linked to obesity has secured a major global contract.
By Greg Wright
Published 31st Mar 2020, 07:30 BST
Updated 31st Mar 2020, 07:30 BST
Stephen OHaraStephen OHara
Stephen OHara

OptiBiotix Health , a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, has entered into an exclusive licence agreement for the use of its OptiBiome weight management ingredient with OptiPharm Pty.

The terms of the licence agreement grant OptiPharm exclusive use of the OptiBiome trademark in 20 markets including Australia, parts of Asia, New Zealand, Middle East, Gulf States and North America. Market exclusivity is linked to minimum order quantities.

Hide Ad
Hide Ad

OptiPharm is a privately owned Australian company, which specialises in weight management and nutrition.

Garry McDonald, Managing Director of OptiPharm, commented: “We are delighted to have completed negotiations with OptiBiotix for access to their patented ingredient OptiBiome for exclusive use in over 20 markets globally.

"In these troubling times and with clinical research identifying a link between excess weight and one’s immune system, OptiPharm are continually searching for innovative ingredients such as OptiBiome, to enhance our Optislim product formulations.

"We look forward to working with OptiBiotix to deliver to our customers the latest in innovation, value and quality.”

Hide Ad
Hide Ad

Dr. Fred Narbel, Managing Director of OptiBiotix’s prebiotics division, commented: “We are very pleased to enter into a commercial agreement with OptiPharm to make OptiBiotix’s award-winning weight management solution available to a wide range of customers through major pharmacy and supermarket retailers and online in over 20 countries."

OptiBiotix Health is led by its chief executive, Stephen O’Hara.